Furthermore, it is inevitable that the patients baseline status in included studies were different, such as age, menopausal status, tumor type, tumor size, lymph node status, the immunohistochemical marker for MVD detecting and duration of follow-up. (HR?=?1.79, 95% CIs 1.31C2.44, hazard ratio, confidence intervals, not available, overall survival, disease-free survival/progress-free survival/metastasis-free survival/recurrence-free survival Association of […]